Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yan, Martinat"'
Autor:
Nicolas Roche, Philippe Devillier, Patrick Berger, Arnaud Bourdin, Daniel Dusser, Jean-François Muir, Yan Martinat, Philippe Terrioux, Bruno Housset
Publikováno v:
ERJ Open Research, Vol 7, Iss 4 (2021)
Chronic obstructive pulmonary disease (COPD) is a main cause of death due to interplaying factors, including comorbidities that interfere with symptoms and response to therapy. It is now admitted that COPD management should be based on clinical sympt
Externí odkaz:
https://doaj.org/article/2f83ff8fb6a54d6d9189d9ae351b222c
Autor:
Romain Kessler, Alain Didier, Mathieu Molimard, A Bourdin, Thierry Chinet, Chantal Raherison, Nicolas Roche, Carey Meredith Suehs, Cécile Chenivesse, Pierre-Régis Burgel, F Couturaud, Gaëtan Deslee, Patrick Berger, Gilles Devouassoux, Christophe Brousse, Philippe Devillier, Pascal Chanez, Yan Martinat, Olivier Le Rouzic
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Objectives Presently, those outcomes that should be prioritised for chronic obstructive pulmonary disease (COPD) exacerbation studies remain unclear. In order to coordinate multicentre studies on eosinophilia-driven corticosteroid therapy for patient
Externí odkaz:
https://doaj.org/article/69426d2d97cc462995eaf4bdbba9be93
Autor:
Arnaud Bourdin, Ian Adcock, Patrick Berger, Philippe Bonniaud, Philippe Chanson, Cécile Chenivesse, Jacques de Blic, Antoine Deschildre, Philippe Devillier, Gilles Devouassoux, Alain Didier, Gilles Garcia, Antoine Magnan, Yan Martinat, Thierry Perez, Nicolas Roche, Camille Taillé, Pierre Val, Pascal Chanez
Publikováno v:
European Respiratory Review, Vol 29, Iss 155 (2020)
Options to achieve oral corticosteroid (OCS)-sparing have been triggering increasing interest since the 1970s because of the side-effects of OCSs, and this has now become achievable with biologics. The Société de Pneumologie de Langue Française wo
Externí odkaz:
https://doaj.org/article/aded1a9ef0904e77a8bde3552258a4e5
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
This was a multicenter, randomized, double-blind within device, parallel-group, dose-ranging study. COPD patients (n = 202; 86% male; mean age: 61 years) were randomized to receive tiotropium 1.25 microg, 2.5 microg, 5 microg, 10 microg, or 20 microg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e0d22fd98c4fc7fb06403f907e418191
https://pubmed.ncbi.nlm.nih.gov/18268929
https://pubmed.ncbi.nlm.nih.gov/18268929